EFIGALO

This brand name is authorized in Estonia, Croatia, Lithuania, Poland

Active ingredients

The drug EFIGALO contains one active pharmaceutical ingredient (API):

1 Fingolimod
UNII G926EC510T - FINGOLIMOD HYDROCHLORIDE

Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes.

Read about Fingolimod

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AE01 Fingolimod L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1807039, 1807040, 1807051, 1807062, 1807073, 1807084, 1807095, 1807107, 1807118
Country: HR Agencija za lijekove i medicinske proizvode Identifier(s): HR-H-665003707
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1092182, 1092183, 1092184, 1092185, 1092186, 1092187, 1092188, 1092189, 1092190, 1092191, 1092192, 1092193, 1092194, 1092195, 1092196, 1092197, 1092198, 1092199, 1092200
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100430163

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.